BioStock: Ultimovacs sees first patient enrolled in DOVACC trial

Ultimovacs has announced that the first patient has been enrolled in a phase II trial designed to assess the impact of the company’s universal cancer vaccine on the standard of maintenance care in ovarian cancer. The primary outcome measure is progression-free survival for UV1 in combination with AstraZeneca’s durvalumab+olaparib versus olaparib alone.

Read the article at biostock.se:

https://www.biostock.se/en/2021/12/ultimovacs-sees-first-patient-enrolled-in-dovacc-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se